In Patients With ST-Segment Elevation Myocardial Infarction, Which Fibrinolytic Agent Is the Safest and Most Effective?

      In patients with ST-segment elevation myocardial infarction (STEMI), when percutaneous coronary intervention is not an option, reperfusion therapy with the fibrinolytic agents tenecteplase, reteplase, or accelerated alteplase (90 minutes of infusion) plus parenteral anticoagulation has better overall safety and efficacy than other regimens.
      To read this article in full you will need to make a payment
      ACEP Member Login
      ACEP Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features.

      Purchase one-time access:

      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Lambert L.
        • Brown K.
        • Segal E.
        • et al.
        Association between timeliness of reperfusion therapy and clinical outcomes in ST-elevation myocardial infarction.
        JAMA. 2010; 303: 2148-2155
        • Gershlick A.H.
        • Banning A.P.
        • Myat A.
        • et al.
        Reperfusion therapy for STEMI: is there still a role for thrombolysis in the era of primary percutaneous coronary intervention?.
        Lancet. 2013; 382: 624-632
        • Berkowitz S.D.
        • Granger C.B.
        • Pieper K.S.
        • et al.
        Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. The Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) I Investigators.
        Circulation. 1997; 95: 2508-2516
        • Huynh T.
        • Cox J.L.
        • Massel D.
        • et al.
        Predictors of intracranial hemorrhage with fibrinolytic therapy in unselected community patients: a report from the FASTRAK II project.
        Am Heart J. 2004; 148: 86-91
        • Mark D.B.
        • Hlatky M.A.
        • Califf R.M.
        • et al.
        Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction.
        N Engl J Med. 1995; 332: 1418-1424
        • Roth G.A.
        • Forouzanfar M.H.
        • Moran A.E.
        • et al.
        Demographic and epidemiologic drivers of global cardiovascular mortality.
        N Engl J Med. 2015; 372: 1333-1341